Fosphenytoin
- Generic Name
- Fosphenytoin
- Brand Names
- Cerebyx, Sesquient
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15N2O6P
- CAS Number
- 93390-81-9
- Unique Ingredient Identifier
- B4SF212641
- Background
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
- Indication
Fosphenytoin is indicated for the treatment of generalized tonic-clonic status epilepticus and for the prevention and treatment of seizures occurring during neurosurgery in adult patients. It can also be substituted, short-term, for oral phenytoin in patients aged two years and older when oral phenytoin administration is not possible.
- Associated Conditions
- Oral phenytoin treatment, Seizures, Status Epilepticus, Generalized tonic-clonic status epilepticus
- Associated Therapies
- -
Phenytoin as Treatment for Acute Exacerbations of Trigeminal Neuralgia - a Prospective Systematic Study of 20 Patients
- Conditions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 15
- Registration Number
- NCT03712254
- Locations
- 🇩🇰
Danish Headache Center, Rigshospitalet - Glostrup, Glostrup, Denmark
Established Status Epilepticus Treatment Trial
- Conditions
- Interventions
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 478
- Registration Number
- NCT01960075
- Locations
- 🇺🇸
Children's Medical Center UTSW, Dallas, Texas, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States
Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
- Conditions
- Interventions
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 434
- Registration Number
- NCT01870024
- Locations
- 🇫🇷
Département d'Anesthésie - Réanimation - SMUR - Hôpital Lariboisière, Paris, France
A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide
- Conditions
- Interventions
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 11
- Registration Number
- NCT01110187
- Locations
- 🇺🇸
UC Health Medical Arts Building, Cincinnati, Ohio, United States
🇺🇸UC Health University Pointe, Cincinnati, Ohio, United States
🇺🇸University Hospital, Cincinnati, Ohio, United States
The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2010-05-24
- Lead Sponsor
- Nobelpharma
- Target Recruit Count
- 40
- Registration Number
- NCT00908453
- Locations
- 🇯🇵
National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures
- Conditions
- Interventions
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- Emory University
- Target Recruit Count
- 158
- Registration Number
- NCT00510783
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.